摘要
Background： Prevention of osteonecrosis （ON） has seldom been addressed. The purpose of this study was to evaluate the effect of resveratrol on preventing steroid-induced ON in rabbits. Methods： Seventy-two rabbits were divided into four groups： （l） NEC （ON） group： thirty rabbits were treated with lipopolysaccharide （LPS） once, then with methylprednisolone （MPS） daily for 3 days; （2） PRE （prevention） group： thirty rabbits were given one dose of LPS, then MPS daily for 3 days, and resveratrol on day 0 and daily for 2 weeks： （3） RES （resveratrol） group： six rabbits were given resveratrol for 2 weeks but without LPS/MPS; （4） CON （control） group： six rabbits were given alcohol for 2 weeks but without LPS/MPS. Levels of plasma tissue-type plasminogen activator （t-PAL plasminogen activator inhibitor 1 （PAl-1）, thrombomodulin （TM）, vascular endothelial growth factor （VEGF）, maximum enhancement （ME） by magnetic resonance imaging, and ON incidence were evaluated. Results： The PRE group had a lower ON incidence than the NEC group, but with no significant differences at 2 weeks and 12 weeks. Tile RES and CON groups did not develop ON. TM and VEGF were significantly higher in the NEC group compared with the PRE group at weeks 1, 2, and 4 （TM： 1 week, P= 0.029; 2 weeks, P= 0.005; and 4 weeks, P = 0.047; VEGF： 1 week, P= 0.039; 2 weeks, P= 0.021; 4 weeks. P = 0.014） but the difference disappeared at 12 weeks. The levels of t-PA and PAl-I were not significantly different between the NEC and PRE groups. The TM, t-PA, PAl-l, and VEGF concentrations in the RES and CON groups did not change over time. Compared to the baseline, ME in the NEC group decreased significantly （P = 0.025） at week 1, increased significantly （P = 0.021） at week 2, and was decreased at week 12. The variance was insignificant in the PRE group. Conclusions： Resveratrol may improve blood supply to bone in a rabbit model of ON of the femoral head via anti-inflammator
Background： Prevention of osteonecrosis （ON） has seldom been addressed. The purpose of this study was to evaluate the effect of resveratrol on preventing steroid-induced ON in rabbits. Methods： Seventy-two rabbits were divided into four groups： （l） NEC （ON） group： thirty rabbits were treated with lipopolysaccharide （LPS） once, then with methylprednisolone （MPS） daily for 3 days; （2） PRE （prevention） group： thirty rabbits were given one dose of LPS, then MPS daily for 3 days, and resveratrol on day 0 and daily for 2 weeks： （3） RES （resveratrol） group： six rabbits were given resveratrol for 2 weeks but without LPS/MPS; （4） CON （control） group： six rabbits were given alcohol for 2 weeks but without LPS/MPS. Levels of plasma tissue-type plasminogen activator （t-PAL plasminogen activator inhibitor 1 （PAl-1）, thrombomodulin （TM）, vascular endothelial growth factor （VEGF）, maximum enhancement （ME） by magnetic resonance imaging, and ON incidence were evaluated. Results： The PRE group had a lower ON incidence than the NEC group, but with no significant differences at 2 weeks and 12 weeks. Tile RES and CON groups did not develop ON. TM and VEGF were significantly higher in the NEC group compared with the PRE group at weeks 1, 2, and 4 （TM： 1 week, P= 0.029; 2 weeks, P= 0.005; and 4 weeks, P = 0.047; VEGF： 1 week, P= 0.039; 2 weeks, P= 0.021; 4 weeks. P = 0.014） but the difference disappeared at 12 weeks. The levels of t-PA and PAl-I were not significantly different between the NEC and PRE groups. The TM, t-PA, PAl-l, and VEGF concentrations in the RES and CON groups did not change over time. Compared to the baseline, ME in the NEC group decreased significantly （P = 0.025） at week 1, increased significantly （P = 0.021） at week 2, and was decreased at week 12. The variance was insignificant in the PRE group. Conclusions： Resveratrol may improve blood supply to bone in a rabbit model of ON of the femoral head via anti-inflammator
